Relmada Therapeutics, Inc. (RLMD) income statement
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.62−0.49 (-15.76%)
Close on Nov 20, 2026Market cap $279.48MP/E –Yield –
Relmada Therapeutics, Inc. financial ratios
See a number that looks wrong?